<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24344" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lisinopril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Olvera Lopez</surname>
            <given-names>Edgardo</given-names>
          </name>
          <aff>Haysmed, The University of Kansas Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pendela</surname>
            <given-names>Venkata Satish</given-names>
          </name>
          <aff>Rochester General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Terrell</surname>
            <given-names>Jamie M.</given-names>
          </name>
          <aff>University of LA Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edgardo Olvera Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Venkata Satish Pendela declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jamie Terrell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24344.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that has been&#x000a0;prescribed for nearly 30 years to manage hypertension and reduce cardiovascular strain. As a competitive ACE inhibitor, lisinopril prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This activity reviews lisinopril's mechanism of action, highlighting its distinct pharmacokinetic parameters and half-life compared to other ACE inhibitors. The discussion also includes lisinopril's FDA-approved indications, off-label uses, contraindications, drug-drug interactions, and potential toxicity. Additionally, dosage recommendations, warnings, and necessary patient monitoring protocols are outlined to support safe administration. This activity also emphasizes the critical role of an interprofessional healthcare team in managing hypertension with lisinopril.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the mechanism of action of lisinopril in the context of hypertension management.</p></list-item><list-item><p>Identify the various indications for&#x000a0;prescribing&#x000a0;lisinopril therapy.</p></list-item><list-item><p>Assess potential adverse effects associated with lisinopril and strategies for monitoring and managing these effects.</p></list-item><list-item><p>Develop collaboration and communication among interprofessional team members to improve the outcomes and treatment efficacy for patients receiving lisinopril therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24344&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24344">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24344.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Lisinopril is classified as an angiotensin-converting enzyme inhibitor and has been available for nearly&#x000a0;3 decades. The following are indications approved by the&#x000a0;United States Food and Drug Administration (FDA) and&#x000a0;conditions&#x000a0;that lisinopril may effectively treat&#x000a0;but are not FDA-approved.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension&#x000a0;<xref ref-type="bibr" rid="article-24344.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Heart failure (adjunctive therapy)&#x000a0;<xref ref-type="bibr" rid="article-24344.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>ST-segment elevation myocardial infarction (STEMI) (if given within 24 hours)&#x000a0;<xref ref-type="bibr" rid="article-24344.r3">[3]</xref><xref ref-type="bibr" rid="article-24344.r4">[4]</xref><xref ref-type="bibr" rid="article-24344.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic nephropathy&#x000a0;<xref ref-type="bibr" rid="article-24344.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Proteinuria, particularly in&#x000a0;patients with immunoglobulin A (IgA) nephropathy</p>
          </list-item>
          <list-item>
            <p>Post-transplant erythrocytosis<bold>&#x000a0;</bold><xref ref-type="bibr" rid="article-24344.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24344.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Lisinopril is a competitive inhibitor of the angiotensin-converting enzyme (ACE) and prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. A&#x000a0;reduction in angiotensin II levels subsequently&#x000a0;suppresses aldosterone secretion, which reduces sodium reabsorption in the collecting duct and potassium excretion. This process may result in a slight increase in serum potassium. By&#x000a0;inhibiting the negative feedback&#x000a0;of angiotensin II, lisinopril increases serum renin activity.<xref ref-type="bibr" rid="article-24344.r8">[8]</xref>&#x000a0;The beneficial effects in patients with hypertension derive from inhibiting the renin-angiotensin-aldosterone system, resulting in&#x000a0;reduced vasopressor and aldosterone activity even in patients with low renin levels. However, ACE also degrades bradykinin. Therefore, ACE inhibitors may increase the risk of angioedema.<xref ref-type="bibr" rid="article-24344.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Lisinopril absorption is unchanged by food. After oral intake, it has low bioavailability, ranging from 10% to 30%. The time to peak concentration can vary from 6 to 8 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;Lisinopril&#x000a0;does not bind to albumin or other proteins, and its distribution in patients with heart failure is poor.<xref ref-type="bibr" rid="article-24344.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Metabolism:</bold> Unlike other ACE inhibitors (eg, enalapril, captopril), lisinopril has a long half-life, is hydrophilic, and is not broken down by the liver.<xref ref-type="bibr" rid="article-24344.r10">[10]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>Lisinopril&#x000a0;is excreted unchanged in the urine.</p>
      </sec>
      <sec id="article-24344.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosages and Strengths</bold>
</p>
        <p>Lisinopril is available as 2.5 mg, 5mg, 10 mg, 20 mg, 30 mg, and 40 mg oral tablets and as a 1 mg/mL oral solution.</p>
        <p>
<bold>Adult Dosage&#x000a0;</bold>
</p>
        <p>The&#x000a0;standard adult dosage ranges from 2.5 to 40 mg daily, depending on the indication.<xref ref-type="bibr" rid="article-24344.r3">[3]</xref><xref ref-type="bibr" rid="article-24344.r4">[4]</xref>&#x000a0;Dosing and administration adjustments are&#x000a0;recommended for patients with various conditions,&#x000a0;such as kidney disease.<xref ref-type="bibr" rid="article-24344.r11">[11]</xref></p>
        <p>
<bold>Hypertension</bold>
</p>
        <p>According to the 2017 guidelines, the American College of Cardiology/American Heart Association (ACC/AHA) recommends<italic toggle="yes">&#x000a0;</italic>ACE inhibitors as first-line agents for managing hypertension.<xref ref-type="bibr" rid="article-24344.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended&#x000a0;initial dose is&#x000a0;10 mg daily, which is increased to 40 mg daily.</p>
          </list-item>
          <list-item>
            <p>If adequate blood pressure control is not achieved with lisinopril alone, a low-dose diuretic can be added. In these cases, the lisinopril&#x000a0;dose can be reduced. The recommended starting dose for adults with hypertension&#x000a0;receiving diuretics is 5 mg once daily.</p>
          </list-item>
        </list>
        <p>
<bold>Heart failure</bold>
</p>
        <p>According to the 2013 ACCF/AHA Guidelines for the Management of Heart Failure&#x000a0;(HF), ACE inhibitors are recommended for all patients with HF with reduced ejection fraction to minimize morbidity and mortality.</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended&#x000a0;initial dose is 2.5 mg daily, with a maximum daily dose of 40 mg.</p>
          </list-item>
          <list-item>
            <p>During the SOLVD trial,&#x000a0;patients in the high-dose group had an overall 8%&#x000a0;reduction in&#x000a0;mortality compared to the low-dose group. The findings of this study have resulted in an inclination towards higher doses.<xref ref-type="bibr" rid="article-24344.r2">[2]</xref><xref ref-type="bibr" rid="article-24344.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>ST-Elevation Myocardial Infarction&#x000a0;</bold>
</p>
        <p>The 2013 ACCF/AHA guidelines strongly recommend administering lisinopril within the first 24 hours for&#x000a0;all hemodynamically stable patients with anterior ST-elevation myocardial infarction, HF, or ejection fraction &#x02264;40%, unless contraindicated.</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended&#x000a0;initial dose is 2.5 to 5 mg daily, with a slow titration to 40 mg daily, or the maximum tolerated dose.<xref ref-type="bibr" rid="article-24344.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Diabetes and hypertension</bold>
</p>
        <p>The American Diabetes Association (ADA) recommends ACE inhibitors as first-line agents for hypertension in patients with diabetes and a urinary albumin-to-creatinine ratio &#x02265;30 mg/g creatinine.<xref ref-type="bibr" rid="article-24344.r13">[13]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended&#x000a0;initial dose is&#x000a0;2.5 to 10 mg daily, depending on blood pressure, and slowly titrated to a maximum daily dose of 40 mg. The&#x000a0;target&#x000a0;proteinuria is less than 1 g/day, as per KDIGO-2013.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic&#x000a0;impairment:&#x000a0;</bold>No dose adjustments are necessary&#x000a0;for patients with hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The manufacturer recommends the following dose adjustments based on creatinine clearance (CrCl):</p>
        <list list-type="bullet">
          <list-item>
            <p>No dose adjustment is required in patients with a&#x000a0;CrCl &#x0003e;30 mL/min.</p>
          </list-item>
          <list-item>
            <p>For patients with a&#x000a0;CrCl of 10 to 30 mL/min, the recommended&#x000a0;initial dose of lisinopril&#x000a0;should be reduced&#x000a0;by 50%.</p>
          </list-item>
          <list-item>
            <p>For patients&#x000a0;with a&#x000a0;CrCl &#x0003c;10 mL/min, the recommended&#x000a0;initial dose is 2.5 mg once daily. This is also the recommended&#x000a0;initial dose for patients on dialysis.<xref ref-type="bibr" rid="article-24344.r11">[11]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold> Lisinopril is pregnancy category class D due to its teratogenic effects (eg, impaired&#x000a0;fetal renal function, oligohydramnios, lung hypoplasia, skeletal malformations, fetal/neonatal death). Thus, its use is contraindicated&#x000a0;for&#x000a0;women who are pregnant or may become&#x000a0;pregnant and are not receiving&#x000a0;appropriate contraception.<xref ref-type="bibr" rid="article-24344.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Manufacturers recommend against&#x000a0;using lisinopril in breastfeeding women because the amount secreted in breast milk and its effects in the breastfed infant is unknown.</p>
        <p><bold>Pediatric patients:</bold>&#x000a0;For children 6 years and older, the initial dose is 0.07 to 0.1 mg/kg once daily, with a maximum initial dose of 5 mg daily.&#x000a0;This dose may be increased&#x000a0;every 1 to 2 weeks to a&#x000a0;maximum tolerated&#x000a0;dose&#x000a0;of 0.6 mg/kg/day or 40 mg/day.<xref ref-type="bibr" rid="article-24344.r15">[15]</xref></p>
      </sec>
      <sec id="article-24344.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse&#x000a0;reactions associated with&#x000a0;ACE inhibitors include hyperkalemia, dry cough, angioedema, hypotension, dizziness, headache, and renal insufficiency.<xref ref-type="bibr" rid="article-24344.r9">[9]</xref><xref ref-type="bibr" rid="article-24344.r16">[16]</xref> These effects may be more common in patients with renal, autoimmune, or collagen vascular diseases.&#x000a0;The AHA/ACCF recommends&#x000a0;caution when prescribing lisinopril&#x000a0;for patients with cardiomyopathy with outflow obstruction, as the&#x000a0;drug may exacerbate symptoms.<xref ref-type="bibr" rid="article-24344.r17">[17]</xref><xref ref-type="bibr" rid="article-24344.r2">[2]</xref>&#x000a0;Historically, ACE inhibitors have&#x000a0;been associated with increased morbidity and mortality in patients with aortic stenosis. However, recent&#x000a0;studies suggest that ACE inhibitors&#x000a0;may be safer than originally thought and even provide some&#x000a0;benefits in certain patients.<xref ref-type="bibr" rid="article-24344.r18">[18]</xref><xref ref-type="bibr" rid="article-24344.r19">[19]</xref><xref ref-type="bibr" rid="article-24344.r20">[20]</xref>&#x000a0;</p>
        <p>ACE inhibitor-induced cough is a dry, nonproductive, hacking cough that usually begins&#x000a0;within months of initiating therapy and resolves within 1 to 4 weeks after discontinuing. Deteriorating renal function can occur in patients whose glomerular function depends on event arteriolar vasoconstriction by angiotensin II. A benign increase in serum creatinine may occur at the beginning of therapy, but medication should only be discontinued if there is a progressive or significant elevation of BUN/creatinine.</p>
        <p>Angioedema is asymmetric swelling of subcutaneous tissue without itching or urticaria involving the face, mouth, and upper airway. ACE inhibitor-induced angioedema can occur anytime during therapy&#x000a0;but most commonly occurs within the first&#x000a0;3 months of treatment. This adverse&#x000a0;reaction is secondary to elevated bradykinin levels by inhibiting ACE, causing vasodilatation and extravasation of plasma into the submucosal tissue, leading to angioedema. The most crucial step in management is to discontinue the ACE inhibitors and&#x000a0;note&#x000a0;ACE inhibitors under the patient's allergies. Immediate symptomatic treatment and airway protection may be necessary.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p><bold>Diuretics:</bold> When initiating lisinopril therapy, diuretics may further reduce blood pressure and lead to hypotension. When coadministered with thiazide-type diuretics or potassium-sparing diuretics (eg, amiloride, spironolactone, triamterene),&#x000a0;lisinopril may increase the risk of hyperkalemia. Therefore, if coadministration of&#x000a0;these diuretics&#x000a0;is necessary, the patient&#x02019;s serum potassium should be monitored frequently.</p>
        <p><bold>Antidiabetics:</bold> Concomitant administration of&#x000a0;antidiabetic medicines (eg, insulins, oral hypoglycemic agents) and lisinopril can increase the risk of hypoglycemia.</p>
        <p><bold>NSAIDs: </bold>Non-steroidal anti-inflammatory agents&#x000a0;can reduce&#x000a0;the antihypertensive effect of ACE inhibitors. However, coadministration of NSAIDs and lisinopril in patients who are older, volume-depleted (including those on diuretic therapy), or renally impaired may worsen renal function&#x000a0;and possibly cause acute renal injury (AKI). This is usually reversible, but renal function should be monitored periodically in patients receiving lisinopril and NSAID therapy.</p>
        <p><bold>Renin-angiotensin system blockers:</bold> Dual blockade of the renin-angiotensin with ACE inhibitors, angiotensin receptor blockers, or aliskiren is associated with higher risks of hyperkalemia, hypotension, and changes in renal function, including AKI, compared to monotherapy. Clinicians should closely monitor blood pressure, electrolytes, and renal function in these patients.</p>
        <p><bold>Lithium:</bold> Lithium toxicity has been reported in patients taking ACE inhibitors and lithium and is usually reversible. Clinicians should monitor serum lithium levels in these patients.</p>
        <p><bold>Rapamycin&#x000a0;inhibitors:</bold> Patients using concomitant mechanistic targets of rapamycin inhibitors (eg, sirolimus, temsirolimus, everolimus) are at increased risk for angioedema.</p>
      </sec>
      <sec id="article-24344.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Lisinopril&#x000a0;is contraindicated for patients with hyperkalemia, a history of angioedema, renal failure with prior lisinopril use, bilateral renal artery stenosis, concomitant use with aliskiren in patients with diabetes mellitus, and&#x000a0;for patients receiving a neprilysin inhibitor or within 36 hours of&#x000a0;taking one.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>When pregnancy is detected, discontinue&#x000a0;lisinopril as soon as possible.</p>
          </list-item>
          <list-item>
            <p>Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p>
          </list-item>
        </list>
        <p>
<bold>Warnings/Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fetal toxicity</p>
          </list-item>
          <list-item>
            <p>Angioedema (concurrent mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitor administration)</p>
          </list-item>
          <list-item>
            <p>Impaired renal function</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Hyperkalemia</p>
          </list-item>
          <list-item>
            <p>Hepatic failure</p>
          </list-item>
          <list-item>
            <p>Risk of allergic reactions due to tartrazine in lisinopril doses of 20 mg, 30 mg, and 40 mg</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24344.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Caution is necessary when prescribing lisinopril&#x000a0;for patients with high-potassium diets or&#x000a0;who are taking other agents that might exacerbate hypotension and hyperkalemia, such as antihypertensive agents or aldosterone antagonists. Although cholestatic jaundice is a rare reaction associated with using the ACE inhibitor captopril, monitoring liver function during lisinopril use may be appropriate. Lisinopril should be discontinued immediately if elevated liver enzymes are detected.<xref ref-type="bibr" rid="article-24344.r21">[21]</xref>&#x000a0;First-dose hypotension is an uncommon adverse effect of ACE inhibitors that clinicians should consider when prescribing lisinopril; a low starting dose is recommended to reduce the risk of this phenomenon.<xref ref-type="bibr" rid="article-24344.r16">[16]</xref>&#x000a0;Clinicians should monitor serum potassium, blood pressure, and blood urea nitrogen/serum creatinine in patients taking lisinopril&#x000a0;for up&#x000a0;to 3 weeks after initiation.</p>
      </sec>
      <sec id="article-24344.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>As&#x000a0;lisinopril metabolism depends on renal excretion, overdose management consists of general supportive care. However, gastric emptying strategies, intravenous fluids, vasopressors, and hemodialysis may also be considered when appropriate. Maintaining optimal blood pressure&#x000a0;using fluids is critical for hypotensive patients.<xref ref-type="bibr" rid="article-24344.r22">[22]</xref>&#x000a0;Some reports suggest&#x000a0;using angiotensin II administration as an alternative supportive treatment for the treatment of ACE inhibitor overdose.<xref ref-type="bibr" rid="article-24344.r23">[23]</xref>&#x000a0;There is no antidote available for lisinopril.</p>
      </sec>
      <sec id="article-24344.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lisinopril has been available for 3 decades and is a relatively safe medication for hypertension. Primary care clinicians, emergency department physicians, internists, and cardiologists often prescribe it. However, the drug requires monitoring. Potassium levels and renal function need periodic monitoring, which clinicians and nursing staff can oversee. Patients should understand how to avoid high-potassium diets, an area where clinicians, nurses, and pharmacists can provide counsel. Women need to be aware of the potential adverse effects of pregnancy while taking lisinopril, making interprofessional counsel from clinicians, nurses, and pharmacists vital. Pharmacists should also check for possible interactions and answer any patient questions. Even though lisinopril is a common and well-tolerated drug, an interprofessional team must optimize safety and therapeutic outcomes while minimizing or preventing adverse events.</p>
      </sec>
      <sec id="article-24344.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24344&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24344">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24344/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24344">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24344.s11">
        <title>References</title>
        <ref id="article-24344.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD008170</fpage>
            <pub-id pub-id-type="pmid">30480768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>1810</fpage>
            <page-range>1810-52</page-range>
            <pub-id pub-id-type="pmid">23741057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>e78</fpage>
            <page-range>e78-e140</page-range>
            <pub-id pub-id-type="pmid">23256914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.</article-title>
            <source>Circulation</source>
            <year>1998</year>
            <month>Jun</month>
            <day>09</day>
            <volume>97</volume>
            <issue>22</issue>
            <fpage>2202</fpage>
            <page-range>2202-12</page-range>
            <pub-id pub-id-type="pmid">9631869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Varghese</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Diabetic Nephropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30480939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlahakos</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Marathias</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Agroyannis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Madias</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Posttransplant erythrocytosis.</article-title>
            <source>Kidney Int</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>1187</fpage>
            <page-range>1187-94</page-range>
            <pub-id pub-id-type="pmid">12631334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regulski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regulska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stanisz</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Murias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gieremek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wzgarda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niznik</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>13</issue>
            <fpage>1764</fpage>
            <page-range>1764-75</page-range>
            <pub-id pub-id-type="pmid">25388457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bezalel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahlab-Guri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sthoeger</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor-induced angioedema.</article-title>
            <source>Am J Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-5</page-range>
            <pub-id pub-id-type="pmid">25058867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warner</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Rush</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Safety profiles of the angiotensin-converting enzyme inhibitors.</article-title>
            <source>Drugs</source>
            <year>1988</year>
            <volume>35 Suppl 5</volume>
            <fpage>89</fpage>
            <page-range>89-97</page-range>
            <pub-id pub-id-type="pmid">3063490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors.</article-title>
            <source>Am J Med</source>
            <year>1988</year>
            <month>Apr</month>
            <day>15</day>
            <volume>84</volume>
            <issue>4A</issue>
            <fpage>16</fpage>
            <page-range>16-23</page-range>
            <pub-id pub-id-type="pmid">3064605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poole-Wilson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Massie</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thygesen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uretsky</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Dec</month>
            <day>07</day>
            <volume>100</volume>
            <issue>23</issue>
            <fpage>2312</fpage>
            <page-range>2312-8</page-range>
            <pub-id pub-id-type="pmid">10587334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marathe</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Close</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>American Diabetes Association Standards of Medical Care in Diabetes 2017.</article-title>
            <source>J Diabetes</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>320</fpage>
            <page-range>320-324</page-range>
            <pub-id pub-id-type="pmid">28070960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moffett</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Denfield</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">24233240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malfait</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Van Aken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>France</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donckerwolcke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vande Walle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">17487821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>MacFadyen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Squire</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.</article-title>
            <source>Am J Cardiol</source>
            <year>1993</year>
            <month>Jun</month>
            <day>24</day>
            <volume>71</volume>
            <issue>17</issue>
            <fpage>57E</fpage>
            <page-range>57E-60E</page-range>
            <pub-id pub-id-type="pmid">8392282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ammirati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Contri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coppini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cecchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frigerio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olivotto</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>1106</fpage>
            <page-range>1106-18</page-range>
            <pub-id pub-id-type="pmid">27109894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elder</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>McAlpine-Scott</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Struthers</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors?</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-14</page-range>
            <pub-id pub-id-type="pmid">23259450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bull</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loudon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karamitsos</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Prendergast</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Banning</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Myerson</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).</article-title>
            <source>Eur Heart J Cardiovasc Imaging</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>834</fpage>
            <page-range>834-41</page-range>
            <pub-id pub-id-type="pmid">25796267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalsgaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kjaergaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goetze</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Clemmensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hassager</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study.</article-title>
            <source>Am Heart J</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <page-range>226-34</page-range>
            <pub-id pub-id-type="pmid">24439984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schattner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kozak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature.</article-title>
            <source>Am J Med Sci</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>322</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">11678523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Cubela</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Lisinopril overdose.</article-title>
            <source>Lancet</source>
            <year>1990</year>
            <month>Feb</month>
            <day>24</day>
            <volume>335</volume>
            <issue>8687</issue>
            <fpage>487</fpage>
            <page-range>487-8</page-range>
            <pub-id pub-id-type="pmid">1968218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24344.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trilli</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Lisinopril overdose and management with intravenous angiotensin II.</article-title>
            <source>Ann Pharmacother</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1165</fpage>
            <page-range>1165-8</page-range>
            <pub-id pub-id-type="pmid">7841571</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
